FDA Brief

Warning letters Drugs

FDA warning letter to

Guangdong Bisutang Biotechnology Co., Ltd.

High riskIssued Oct 27Posted Nov 3Center for Drug Evaluation and Research (CDER)

Guangdong Bisutang Biotechnology refused FDA records requests for OTC drugs and used a cancelled color additive in sunscreen.

What happened

FDA reviewed import records and the firm's drug product listing, which showed multiple U.S. shipments declaring the firm as manufacturer. FDA sent a records request on May 1, 2026, and follow-ups, including a May 28 UPS letter signed for by a facility representative, but the company did not respond. FDA also found that the "XUEYI SKIN CARE" sunscreen contains cancelled color additive CI 11680 (Ext. D&C Yellow No. 5) and placed all the firm's drugs on Import Alert 66-79 on July 31, 2026.

What FDA found

  1. The company refused to provide access to or copies of records FDA requested about its drug manufacturing.

    Section 704(a)(4) and section 301(e) of the FD&C Act (21 U.S.C. 374(a)(4), 331(e))
  2. Its "XUEYI SKIN CARE" sunscreen contains Ext. D&C Yellow No. 5 (CI 11680), a color additive FDA cancelled in 1966, so FDA calls the drug adulterated (unsafe under the law).

    Section 501(a)(4)(A) of the FD&C Act; 21 CFR 81.30(d)
  3. FDA found import entry discrepancies: the firm's drug product listing was not correctly declared, and entries should name the manufacturer and use its registration and product listing numbers.

    21 CFR 1.74(a)(1)

What FDA wants

FDA tells the company to respond in writing within 15 working days to CDER-OC-OMQ-Communications@fda.hhs.gov, with FEI 3031796296 and ATTN: Lynnsey Renn, and to include any information showing the products are not in violation. The company may also ask FDA to schedule an inspection.

Who should pay attention

  • brands that buy OTC drugs or sunscreens from this manufacturer
  • U.S. importers and entry filers of its products
  • companies relying on foreign drug makers' records responses

This is a summary. Read the original letter on fda.gov.